Dapagliflozin Versus Dexamethasone Role in Pre-operative Management of Non- Diabetic Brain Tumor Patients

Launched by TANTA UNIVERSITY · Dec 24, 2024

Keywords

ClinConnect Summary

This clinical trial is focused on comparing two medications, dapagliflozin and dexamethasone, to see which one is better for managing non-diabetic patients with glioma (a type of brain tumor) before they have surgery. Glioma patients often take a medication called levetiracetam to help control seizures, and this study aims to find out which treatment works best for them in the time leading up to their operation.

To be eligible for this trial, participants need to be adults aged between 18 and 75 years who have been diagnosed with glioma and are currently taking levetiracetam. The researchers will confirm the diagnosis through a physical exam and an MRI scan of the brain. The trial is not yet recruiting participants, but once it starts, those who join can expect to receive either dapagliflozin or dexamethasone and to be monitored closely by the medical team. It’s important to note that certain individuals, such as those over 75, pregnant or breastfeeding women, and patients with diabetes or severe kidney issues, will not be able to participate.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Males \& females.
• • Age: between 18 and 75 years old.
• * Pre-operative non-diabetic glioma patients on levetiracetam. • Diagnosis will be confirmed by:
• • The initial clinical examination.
• • Magnetic resonance imaging of the brain (MRI) with contrast.
• Exclusion Criteria:
• • Age: \> 75 years old, and \<18 years old.
• • Breast feeding female. • Pregnant female.
• • eGFR\< 30 mL/minute/1.73 m2.
• • Patients with diabetes mellitus.
• • Patients with diabetic ketoacidosis.
• • Patients with urinary tract infection.
• • Dehydrated patients till normalized.
• • Lower limb amputation patients.
• • SGLT2 inhibitors hypersensitivity.
• • Severe hepatic patients (child-plug score class-c).